M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
The introduction of direct acting antiviral (DAA) agents and the opioid epidemic have resulted in an increased interest in liver transplantation (LT) of organs from donors with hepatitis C virus (HCV)-related viremia. 1 Subsequently, a case was reported where a HCV-V liver was transplanted into a HCV seronegative recipient. 3 In collaboration with OPTN/UNOS we identified cases when HCV-V deceased donor livers were transplanted into HCV seronegative recipients.
Methods
Using the OPTN/UNOS database, we analyzed utilization trends in HCV-V and Demographics and clinical characteristics were compared among HCV-V and HCV-NV donor livers. Chi-square and Mann-Whitney U tests were used for comparisons between cohorts. Statistical significance was reached with P < .05. (Table) , with the majority occurring in 2017 (n=22, 73.3%).
Results

From
Drug overdose deaths accounted for over half of all HCV-V deceased donor livers, a significantly higher proportion compared to all other deceased donor livers.
Although HCV-V livers had a higher risk for disease transmission than HCV seropositive non-viremic (NV) and HCV seronegative livers, the donors of HCV-V livers were younger in age with lower liver donor risk index (LDRI) or risk for graft failure (Table 1) . Furthermore, limited one-year post-transplant recipient survival was comparable (HCV-V liver transplanted into HCV seronegative recipient, 92.2%
versus HCV-NV liver transplanted into HCV seronegative recipient, 91.9%; P =.83).
Compared to HCV seronegative livers, HCV seropositive livers suffered a significantly higher discard rate (HCV seropositive, 30.7% versus HCV seronegative, 13.8%; P <.001). Among HCV-NV livers there was a sharp annual decline in discard rate from 31.2% in 2016 to 24.8% in 2017. In contrast, annual discard rates for HCV-V livers with NAT positivity continued to remain above 30% without any discernible decline.
Discussion
In recent years, there has been a growing interest in using HCV-V deceased donor livers. 4 We particularly among donors who died due to drug overdose. 6 With the option to use DAA-based therapy immediately following LT, HCV infection can be treated preemptively without significant hepatic dysfunction. 7 In addition, donor liver biopsies at the time of organ procurement can help evaluate for underlying liver fibrosis and steatosis which can aid in the decision to utilize these procured donor livers. The timing and cost of DAA therapy, insurance authorization process, and donor and recipient selection remain undefined. Therefore, it is recommended that an informed consent be obtained, and DAA therapy approval by insurance authorized or treatment conducted in the context of a clinical trial. 
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